全文获取类型
收费全文 | 123271篇 |
免费 | 10764篇 |
国内免费 | 7762篇 |
学科分类
医药卫生 | 141797篇 |
出版年
2024年 | 235篇 |
2023年 | 1628篇 |
2022年 | 3192篇 |
2021年 | 5986篇 |
2020年 | 4371篇 |
2019年 | 3892篇 |
2018年 | 4241篇 |
2017年 | 3630篇 |
2016年 | 3506篇 |
2015年 | 5397篇 |
2014年 | 6855篇 |
2013年 | 6070篇 |
2012年 | 8998篇 |
2011年 | 10017篇 |
2010年 | 6075篇 |
2009年 | 4752篇 |
2008年 | 6385篇 |
2007年 | 6601篇 |
2006年 | 6487篇 |
2005年 | 6782篇 |
2004年 | 4514篇 |
2003年 | 4079篇 |
2002年 | 3531篇 |
2001年 | 2913篇 |
2000年 | 3148篇 |
1999年 | 3204篇 |
1998年 | 1868篇 |
1997年 | 1787篇 |
1996年 | 1546篇 |
1995年 | 1395篇 |
1994年 | 1179篇 |
1993年 | 751篇 |
1992年 | 1123篇 |
1991年 | 892篇 |
1990年 | 776篇 |
1989年 | 677篇 |
1988年 | 662篇 |
1987年 | 565篇 |
1986年 | 468篇 |
1985年 | 354篇 |
1984年 | 217篇 |
1983年 | 166篇 |
1982年 | 92篇 |
1981年 | 103篇 |
1980年 | 85篇 |
1979年 | 120篇 |
1978年 | 54篇 |
1977年 | 56篇 |
1975年 | 44篇 |
1974年 | 45篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
11.
Qiangsheng He Chongfei Huang Xiwen Qin Yuanyuan Yu Di Tang Junjie Huang Zi Chong Kuo Yuyao Ling Deli Mao Bin Xia Wenjing Li Kuiqing Lu Man Yang Yulong He Wenbo Meng Jinqiu Yuan Yihang Pan 《International journal of cancer. Journal international du cancer》2023,153(5):942-949
Recent epidemiological studies suggested that proton pump inhibitor (PPI) use was associated with an increased risk of biliary tract cancer (BTC), however, confounders were not adequately controlled. Our study aimed to evaluate PPI use and subsequent risk of BTC and its subtypes in three well-established cohorts. We conducted a pooled analysis of the subjects free of cancers in UK Biobank (n = 463 643), Nurses' Health Study (NHS, n = 80 235) and NHS II (n = 95 869). Propensity score weighted Cox models were used to estimate marginal HRs of PPIs use on BTC risk, accounting for potential confounders. We documented 284 BTC cases in UK Biobank (median follow-up: 7.6 years), and 91 cases in NHS and NHS II cohorts (median follow-up: 15.8 years). In UK biobank, PPI users had a 96% higher risk of BTC compared to nonusers in crude model (HR 1.96, 95% CI 1.44-2.66), but the effect was attenuated to null after adjusting for potential confounders (HR 0.95, 95% CI 0.60-1.49). PPI use was not associated with risk of BTC in the pooled analysis of three cohorts (HR 0.93, 95% CI 0.60-1.43). We also observed no associations between PPI use with risk of intrahepatic (HR 1.00, 95% CI 0.49-2.04), extrahepatic bile duct (HR 1.09, 95% CI 0.52-2.27) and gallbladder cancers (HR 0.66, 95% CI 0.26-1.66) in UK Biobank. In summary, regular use of PPIs was not associated with the risk of BTC and its subtypes. 相似文献
12.
The research and development of penicillin started with difficulty before 1949 and achieved certain results. In 1951, after the founding of the People's Republic of China, Zhang Weishen, as the only Chinese scientist who had been trained and worked in a penicillin research and development center in the United States for many years, overcame many difficulties and returned to China. In 1953, with the efforts of Zhang Weishen and his colleagues, China realized the industrialized production of penicillin, alleviating the urgent needs of the masses. Antibiotics has also become the first discipline to achieve major scientific and technological achievements after the founding of the New China. In the mid-1950s, the technical breakthrough in the localization of lactose substitutes marked the localization of the raw materials of the penicillin-producing culture medium, which paved the way for the industrialized production of penicillin with Chinese characteristics. Antibiotics have become one of the most widely used and affordable drugs for hundreds of millions of patients in China, and China has since ended the humiliating history of the “Sick Man of East Asia". 相似文献
13.
目的 探讨滋肾育胎丸加减方预防抗磷脂抗体(ACA)阳性者不良妊娠结局的效果及机制研究。方法 选取2016年2月至2019年2月我院收治的89例ACA阳性,先兆性流产或有习惯性流产(RSA)史患者,将采用西医治疗的40例作为对照组,将采用西医联合滋肾育胎丸加减方治疗的49例作为观察组,比较两组中医证候疗效、中医证候积分、ACA-IgA、ACA-IgM、ACA-IgG、凝血指标[血小板聚集功能(PAF)、活化蛋白C(PC)、抗凝血酶(AT)、纤溶酶原激活抑制物-1(PAI-1)]、Th1/Th2细胞因子[干扰素γ(IFN-γ)、白介素-2(IL-2)、白介素-4(IL-4)、白介素-10(IL-10)]、妊娠结局、安全性。结果 治疗2周后检测ACA,观察组2例未降低,对照组11例未降低,观察组未降低患者占比低于对照组(P<0.05);观察组总有效率100.00%高于对照组85.00%(P<0.05);观察组治疗4周、7周后中医证候积分低于对照组(P<0.05);观察组治疗4周、7周后ACA-IgA、ACA-IgM、ACA-IgG低于对照组(P<0.05);观察组治疗4周、7周后PAF、PAI-1低于对照组,PC、AT高于对照组(P<0.05);观察组治疗4周、7周后IFN-γ、IL-2低于对照组,IL-4、IL-10高于对照组(P<0.05);观察组活产率95.92%高于对照组80.00%(P<0.05);组间不良反应总发生率比较,差异无统计学意义(P>0.05)。结论 动态监测ACA对滋肾育胎丸加减方精准应用具有指导意义,指导滋肾育胎丸加减方通过调理脏腑、气血、经络功能,改善先兆性流产或有RSA史患者临床症状及凝血因子指标,降低ACA水平,并可改善患者免疫耐受功能,提高胎儿活产率,且安全性高。 相似文献
14.
15.
16.
Yan Gao Shi-Feng Chu Zhao Zhang Qi-Di Ai Cong-Yuan Xia Hui-Yong Huang 《Journal of Asian natural products research》2019,21(8):782-797
Inappropriate use of acetaminophen (APAP) can lead to morbidity and mortality secondary to hepatic necrosis. Ginsenoside Rg1 is a major active ingredient in processed Panax ginseng, which is proved to elicit biological effects. We hypothesized the beneficial effect of Rg1 on APAP-mediated hepatotoxicity was through Nrf2/ARE pathway. The study was conducted in cells and mice, comparing the actions of Rg1. Rg1 significantly improved cell survival rates and promoted the expression of antioxidant proteins. Meanwhile, Rg1 reduced the excessive ROS and the occurrence of cell apoptosis, which were related to Nrf2/ARE pathway. Expression of Nrf2 has a certain cell specificity.
17.
18.
目的探讨人工弓状线切开技术在变异弓状线病例腹腔镜全腹膜外腹股沟疝修补术(TEP)应用的可靠性、安全性和有效性。
方法回顾性分析2016年7月至2019年8月广东医科大学茶山医院施行TEP的60例弓状线变异患者资料,在脐与耻骨联合连线中点人为切开腹直肌后鞘及其后面的腹横筋膜创建一条人工弓状线,并对其后面的腹膜前间隙进分离。影像记录弓状线的形态和手术步骤。
结果低位弓状线50例(83.3%),位于脐下8~12 cm,表现为不完整的腹直肌后鞘,向下呈逐渐变薄、变少的散在纤维。无弓状线10例(16.7%),有完整的腹直肌后鞘并一直延伸至耻骨。以人工弓状线为界分为两个层面,前面的是腹直肌后间隙,后面是腹膜前间隙,位于腹横筋膜(含有后鞘)与腹膜前筋膜浅层之间,是TEP理想的分离层面,沿此间隙向下分离与Retzius间隙相连,然后向外分离Bogros间隙。本组平均手术时间(130±15)min,术中腹膜损伤率8.3%(5/60)。术后发生血肿3例,血清肿2例,皮下气肿3例,无慢性疼痛病例。术后平均随访25个月,无复发病例。
结论人工弓状线切开技术在低位和无弓状线患者的TEP手术中安全有效、简单可靠,值得推广。 相似文献
19.
ABSTRACTIn clinical trials, selection of appropriate study endpoints is critical for an accurate and reliable evaluation of safety and effectiveness of a test treatment under investigation. In practice, however, there are usually multiple endpoints available for measurement of disease status and/or therapeutic effect of the test treatment under study. For example, in cancer clinical trials, overall survival, response rate, and/or time to disease progression are usually considered as primary clinical endpoints for evaluation of safety and effectiveness of the test treatment under investigation. Once the study endpoints have been selected, sample size required for achieving a desired power is then determined. It, however, should be noted that different study endpoints may result in different sample sizes. In practice, it is usually not clear which study endpoint can best inform the disease status and measure the treatment effect. Moreover, different study endpoints may not translate one another although they may be highly correlated one another. In this article, we intend to develop an innovative endpoint namely therapeutic index based on a utility function to combine and utilize information collected from all study endpoints. Statistical properties and performances of the proposed therapeutic index are evaluated theoretically. A numerical example concerning a cancer clinical trial is given to illustrate the use of the proposed therapeutic index. 相似文献
20.
Whitney S. Brandt Wanpu Yan Jian Zhou Kay See Tan Joseph Montecalvo Bernard J. Park Prasad S. Adusumilli James Huang Matthew J. Bott Valerie W. Rusch Daniela Molena William D. Travis Mark G. Kris Jamie E. Chaft David R. Jones 《The Journal of thoracic and cardiovascular surgery》2019,157(2):743-753.e3